Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 11, 2012, Pages 5599-5603

  Tong, Lin ^a   Yang, Xue Xi ^a   Liu, Min Feng ^a   Yao, Guang Yu ^a   Dong, Jian Yu ^a   Ye, Chang Sheng ^a   Li, Ming ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; EGFR; Ks; Mutation; PIK3CA

Indexed keywords

EID: 84874042040     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.11.5599     Document Type: Article

References (37)

1. Batzer AG, Rotin D, Urena JM, et al (1994). Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol, 14, 5192-201.
2. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al (2007). Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res, 67, 2643-8.
3. Chan TO, Rittenhouse SE, Tsichlis PN (1999). AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu Rev Biochem, 68, 965-1014.
4. Cheang MC, Voduc D, Bajdik C, et al (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res, 14, 1368-76.
5. Davies H, Bignell GR, Cox C et al (2002). Mutations of the BRAF gene in human cancer. Nature, 417, 949-54. Dickler MN, Cobleigh MA, Miller KD, et al (2009). Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat, 115, 115-21.
6. Dickler MN, Cobleigh MA, Miller KD, et al (2009). Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer. Breast Cancer Res Treat, 115, 115-21.
7. Dickler MN, Rugo HS, Eberle CA, et al (2008). A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res, 14, 7878-83. Dunlap J, Le C, Shukla, A, et al (2010). Phosphatidylinositol-3- kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat, 120, 409-18.
8. Dunlap J, Le C, Shukla, A, et al (2010). Phosphatidylinositol-3- kinase and AKT1 mutations occur early in breast carcinoma. Breast Cancer Res Treat, 120, 409-18.
9. Gollamudi R, Ghalib MH, Desai KK, et al. (2010). Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs, 28, 641-9.
10. Green MD, Francis PA, Gebski V, et al (2009). Gefitinib treatment in hormone-resistant and hormone receptornegative advanced breast cancer. Ann Oncol, 20(11), 1813-1817.
11. Gutteridge E, Agrawal A, Nicholson R, et al (2010). The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study. Int J Cancer, 126(8), 1806-16.
12. Kadota M, Sato M, Duncan B, et al (2009). Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res, 69, 7357-65.
13. Kalinsky K, Jacks LM, Heguy A, et al (2009). PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res, 15, 5049-59.
14. Kan Z, Jaiswal BS, Stinson J, et al. (2010). Diverse somatic mutation patterns and pathway alterations in human cancers. Nature, 466, 869-73.
15. Kehr EL, Jorns JM, Ang D, et al (2012). Mucinous breast carcinomas lack PIK3CA and AKT1 mutations. Hum Pathol.
16. Kononen J, Bubendorf L, Kallioniemi A, et al (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4, 844-7.
17. Lee JW, Soung YH, Kim SY, et al (2005). PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene, 24, 1477-80.
18. Leong SP, Shen ZZ, Liu TJ, et al (2010). Is breast cancer the same disease in Asian and Western countries? World J Surg, 34, 2308-24.
19. Li SY, Rong M, Grieu F, et al (2006). PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat, 96, 91-5.
20. Liang X, Lau QC, Salto-Tellez M, et al (2006).Mutational hotspot in exon 20 of PIK3CA in breast cancer among Singapore Chinese. Cancer Biol Ther, 5, 544-8.
21. Lowenstein EJ, Daly RJ, Batzer AG, et al (1992). The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell, 70, 431-42.
22. Lv N, Xie X, Ge Q, et al (2011). Epidermal growth factor receptor in breast carcinoma: association between gene copy number and mutations. Diagn Pathol, 6, 118.
23. MacConaill LE, Campbell CD, Kehoe S M, et al (2009). Profiling critical cancer gene mutations in clinical tumor samples. PLoS One, 4, e7887.
24. Martin V, Botta F, Zanellato E, et al (2012). Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features. Histol Histopathol, 27, 785-92.
25. Maruyama N, Miyoshi Y, Taguchi T, et al (2007). Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin Cancer Res, 13, 408-14.
26. Modi S, D'Andrea G, Norton L, et al (2006). A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer, 7, 270-7.
27. Perez-Tenorio G, Alkhori L, Olsson B, et al (2007). PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin Cancer Res, 13, 3577-84.
28. Saal LH, Holm K, Maurer M, et al (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res, 65, 2554-9.
29. Sholl LM, Xiao Y, Joshi V, et al (2010). EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol, 133, 922-34.
30. Sinn HP, Helmchen B, et al (2010). [TNM classification of breast cancer: changes and comments on the 7th edition]. Pathologe, 31, 361-6.
31. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res, 68, 6084-91.
32. Troxell ML, Levine J, Beadling C, et al (2010). High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast. Mod Pathol, 23, 27-37.
33. Tsuda H, Morita D, Kimura M, et al. (2005). Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci, 96, 48-53.
34. Tsutsui S, Kataoka A, Ohno S, et al (2002). Prognostic and predictive value of epidermal growth factor receptor in recurrent breast cancer. Clin Cancer Res, 8, 3454-60.
35. Uramoto H, Shimokawa H, Nagata Y, et al (2010). EGFRactivating mutations are not present in breast tumors of Japanese patients. Anticancer Res, 30, 4219-22.
36. Walker RA, Dearing SJ (1999). Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat, 53, 167-76.
37. Wang L, Zhang Q, Zhang J, et al (2011). PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 11, 248.